BridgeBio's Attruby Is Working. The Question Is Who Collects the Cash

BridgeBio Pharma is having the kind of year rare-disease investors dream about. Its lead drug, Attruby (acoramidis), an oral stabilizer of the transthyretin protein used to treat the amyloid cardiomyopathy known as ATTR-CM, generated $222.4 million of U.S. net product revenue in the second quarter of 2026 — up from $71.5 million a year earlier and marking another quarter of more than $35 million in sequential growth . Three separate FDA decisions are stacked over the next twelve months, and a major competitor's attempt to leapfrog the stabilizer class just failed in a pivotal trial. The stock, at roughly $80 against a 52-week range of $48.78 to $93.42, has more than doubled off its lows and carries a market capitalization near $15.7 billion .

The Tenzing house view — and the reason this piece is worth your time — is that all of this is genuinely favorable, and that the near-term skew is positive into a dense catalyst calendar. I largely agree with the commercial read. But the harder, less-discussed truth about BridgeBio is that the equity sitting on top of this franchise is a thin residual behind a capital structure that private-credit and private-equity sponsors engineered to harvest the ramp first. The three points a reader should leave with: the Attruby cadence is a durable first-line annuity, not a decaying switch trade; the competitive and regulatory backdrop improved materially this summer; and yet the cash those wins throw off increasingly accrues to royalty holders, a 7% preferred, and a convertible stack before common holders touch it. The commercial story is a long. The equity is a more complicated call.

What BridgeBio Actually Is, and How It Reports

BridgeBio is a commercial-stage biopharmaceutical company built around genetic diseases, and its revenue lands in three lines. The dominant one is product revenue — essentially all U.S. Attruby — which was $362.4 million, or roughly 72% of the $502.1 million FY25 total, and has since scaled far higher; in Q2'26 alone Attruby net product revenue was $222.4 million . The second is license and services revenue, a lumpy line tied largely to the Bayer partnership for ex-U.S. acoramidis (branded Beyonttra) and historically inflated by one-time milestones — it was only $5.8 million in Q2'26 against a year-ago quarter that carried a...